



ISSN: 2349-5448

Intercontinental Journal of Pharmaceutical Investigations and Research (ICJPIR)

ICJPIR | Vol.15 | Issue 1 | Jan - Mar -2026

www.icjpir.com

DOI: <https://doi.org/10.61096/icjpir.v13.iss1.2026.89-96>

Stability-indicating Isocratic RP-HPLC Method for Simultaneous Quantification of Olaparib and Paracetamol: Development, Validation and Forced Degradation Study

J.Sai Manikantashwarji*, M.Bhaskar¹, N.Sandhya rani², G.Bhavani³, K.Srivani⁴, Priyanka.K⁵

Smt. Sarojini Ramulamma College of Pharmacy, Seshadrinagar, Mahabubnagar, Telangana-509001, India

*Corresponding Author: J. Sai Manikantashwarji
Email: bhaskarsrcp@gmail.com



Published on:
28.03.2026
Published by:
Futuristic
Publications
2026| All rights
reserved.



Creative Commons
Attribution 4.0
International
License.

Abstract: An isocratic reversed-phase HPLC (RP-HPLC) method with UV detection was developed and validated for the simultaneous quantification of olaparib (OLA) and paracetamol (PCM) in laboratory-prepared mixtures, with demonstration of stability-indicating performance. Chromatographic separation was achieved on a C18 column (250 × 4.6 mm, 5 μm) using a mobile phase of acetonitrile and 0.02 M phosphate buffer (55:45, v/v; pH 3.0 ± 0.1) at a flow rate of 1.0 mL/min, column temperature of 30 °C and detection at 250 nm. Retention times were approximately 3.18 min for PCM and 6.45 min for OLA, with resolution >4 between peaks. The method was validated according to ICH Q2 (R1) for specificity, linearity, accuracy, precision, sensitivity and robustness. Linearity was established over 5–50 μg/mL for OLA and 2.5–25 μg/mL for PCM with regression coefficients >0.999. Recoveries at 80–120% levels were 99.40–99.75% for OLA and 99.58–99.63% for PCM, with %RSD <1.0. Intra- and inter-day precision studies provided assay %RSD ≤0.71 for both analytes. LOD/LOQ values were approximately 0.5/1.5 μg/mL for OLA and 0.3/1.0 μg/mL for PCM. Forced degradation under acidic, alkaline, oxidative, neutral, thermal and photolytic stress produced 2.2–19.4% degradation, while analyte peaks remained well resolved from degradation peaks and mass balance approached 100%. The validated method is suitable for routine assay, compatibility studies and stability testing of OLA–PCM mixtures.

Keywords: Olaparib; Paracetamol; RP-HPLC; Stability-indicating; Forced degradation; ICH Q2(R1); Method validation

1. Introduction

Olaparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor widely used in the treatment of malignancies associated with defects in DNA repair pathways. In clinical practice, symptomatic medications such as paracetamol are frequently co-administered with olaparib for the management of pain and fever. Therefore, the development of reliable analytical methods capable of simultaneously estimating olaparib and paracetamol is important during formulation development, compatibility studies, and stability assessment of combined pharmaceutical systems. Such methods are particularly valuable when adequate chromatographic selectivity is required in the presence of potential degradation products.

Several HPLC methods have been reported for the individual estimation of olaparib and paracetamol. However, simultaneous stability-indicating methods for both drugs under ICH-recommended stress conditions remain limited. Many of the reported chromatographic procedures employ gradient elution, longer run times, or different detection conditions, which may not be suitable for routine high-

throughput analytical applications. Therefore, there is a continuing need for a simple isocratic RP-HPLC method capable of providing rapid analysis, satisfactory sensitivity, and effective separation of the analytes from their degradation products.

Previously reported stability-indicating RP-HPLC methods for olaparib in bulk drug and dosage forms commonly utilise C18 columns with gradient elution systems. Forced degradation studies have demonstrated that olaparib is particularly susceptible to hydrolytic and oxidative degradation. In addition, advanced analytical techniques such as LC-MS/MS and UPLC have been employed for the detection and characterisation of olaparib and its degradation products, offering high sensitivity and structural confirmation. Bioanalytical methods developed for olaparib in plasma have also supported pharmacokinetic investigations and demonstrated the chemical instability of the drug under certain storage conditions.

Similarly, numerous UV spectrophotometric and HPLC methods have been reported for the analysis of paracetamol in bulk drugs and pharmaceutical formulations. Conventional RP-HPLC methods for paracetamol tablets and syrups generally utilise C18 columns with acetonitrile-buffer mobile phases and UV detection around 243 nm. Spectrophotometric methods typically involve direct UV measurement within the range of 243–246 nm. In addition, simultaneous RP-HPLC methods for paracetamol in combination with drugs such as ibuprofen and lornoxicam have also been described in the literature.

A comprehensive literature survey revealed that several stability-indicating analytical methods are available for olaparib alone or in combination with antineoplastic agents, while numerous analytical methods have been reported for paracetamol alone or in combination with nonsteroidal anti-inflammatory and antispasmodic drugs. However, no simple isocratic RP-HPLC method has been reported for the simultaneous estimation of olaparib and paracetamol with systematic forced degradation analysis. Therefore, the present study aimed to develop a rapid, simple, and stability-indicating isocratic RP-HPLC method with UV detection for the simultaneous quantification of olaparib and paracetamol. The developed method was validated according to ICH Q2 (R1) guidelines and evaluated under hydrolytic, oxidative, thermal, and photolytic stress conditions to establish its stability-indicating capability.

2. Materials and methods

2.1 Chemicals and reagents

Olaparib (OLA) working standard with a stated purity of not less than 99% was procured from a reputed manufacturer and used without further purification. Paracetamol (PCM) of pharmacopoeial grade, with an assay value of at least 99%, was obtained from an approved supplier. All solvents and reagents employed in the study were of analytical or HPLC grade as appropriate. Acetonitrile, methanol and water (Milli-Q) were used as the principal chromatographic solvents. Potassium dihydrogen phosphate and orthophosphoric acid were used for preparation and pH adjustment of the aqueous buffer phase. Hydrogen peroxide solution (30% w/v) served as the oxidizing agent for forced degradation, whereas sodium hydroxide and hydrochloric acid were employed for alkaline and acidic hydrolysis, respectively. Additional materials included 0.45 µm PVDF membrane filters and syringe filters for sample clarification, along with standard volumetric glassware and micropipettes for accurate dilutions.

2.2 Instrumentation

Chromatographic analysis was performed using a Shimadzu HPLC system equipped with a UV detector and data acquisition software (details in Table 1).

2.3 Chromatographic conditions

Optimised chromatographic conditions are summarised in Table 2. Briefly, separation was carried out on a C18 column (250 × 4.6 mm, 5 µm) at 30 °C using an isocratic mobile phase of acetonitrile and 0.02 M phosphate buffer (55:45, v/v) adjusted to pH 3.0 ± 0.1. The flow rate was 1.0 mL/min, the injection volume was 20 µL and detection was performed at 250 nm.

2.4 Preparation of standards

Stock solutions (1000 µg/mL) of olaparib and paracetamol were prepared separately by dissolving 25 mg of each drug in methanol in a 25 mL volumetric flask, assisted by sonication, and diluting to volume with methanol. Mixed working standard solution (100 µg/mL of each analyte) was prepared by appropriate dilution with mobile phase. Serial dilutions with mobile phase were used to obtain calibration levels of 5–50 µg/mL for olaparib and 2.5–25 µg/mL for paracetamol.

2.5 Sample preparation

To simulate a laboratory mixture, a blend corresponding to 10 mg of olaparib and 500 mg of paracetamol was transferred to a 100 mL volumetric flask, extracted with methanol (sonication ~15 min), cooled, diluted to volume with methanol, filtered through a 0.45 µm membrane filter and further diluted with mobile phase to yield sample concentrations within the validated range (20 µg/mL of olaparib and 10 µg/mL of paracetamol).

2.6 Method validation

The method was validated in accordance with ICH Q2 (R1) for system suitability, specificity, linearity, accuracy, precision (repeatability and intermediate precision), limits of detection (LOD) and quantitation (LOQ), and robustness. System suitability was evaluated by six replicate injections of the mixed working standard at 100% test level. Accuracy was assessed by recovery at 80%, 100% and 120% levels (n=3). Precision was assessed at the same levels for intra-day and inter-day variation. LOD and LOQ were estimated using the standard deviation of response and the slope of calibration curves. Robustness was assessed by deliberate small variations in flow rate, organic composition and detection wavelength.

2.7 Forced degradation studies

Forced degradation was performed on mixed standard solutions to demonstrate stability-indicating capability in line with ICH Q1A (R2), applying acidic, alkaline, oxidative, neutral hydrolytic, thermal and photolytic stress, targeting ~10–20% degradation.

2.8 Statistical analysis

Calibration curves were obtained by linear regression of peak area versus concentration and regression equations with coefficients of determination (R^2) were calculated.

Table 1: Major instruments and equipment used.

S. No.	Instrument	Model/Make	Purpose
1	HPLC with UV detector	Shimadzu 20AD	Chromatographic analysis
2	C18 column 250 × 4.6 mm, 5 µm	Inertsil ODS-3	Stationary phase
3	Analytical balance (0.1 mg)	Shimadzu AY220	Weighing of standards/samples
4	Ultrasonicator	PCI/Microclean	Dissolution, degassing
5	pH meter	Eutech pH Tutor	Adjustment of buffer pH
6	Stability chamber	Thermo/Equivalent	Forced degradation studies

Table 2: Optimised chromatographic conditions for olaparib and paracetamol.

Parameter	Condition
Stationary phase	C18, 250 × 4.6 mm, 5 µm
Mobile phase	Acetonitrile : 0.02 M phosphate buffer (55:45 v/v)
pH of buffer	3.0 ± 0.1
Flow rate	1.0 mL/min
Detection wavelength	250 nm
Column temperature	30 °C
Injection volume	20 µL
Run time	10 min

3. Results and discussion

3.1 Method development and chromatographic performance

Selection of the detection wavelength was based on recorded UV spectra of both analytes and a compromise wavelength of 250 nm was selected to provide adequate response for both olaparib and paracetamol. Under the final conditions (Table 2), paracetamol eluted at approximately 3.18 ± 0.04 min and olaparib at 6.45 ± 0.05 min. System suitability criteria were met, including plate counts >2000, tailing factor ≤ 2 and resolution >2 (Table 3).

3.2 Specificity and stability-indicating capability

Specificity was demonstrated by the absence of interfering peaks at the retention times of the analytes in blank and placebo chromatograms and by baseline separation of olaparib and paracetamol from degradation products generated under multiple stress conditions. Forced degradation resulted in 2.2–19.4% degradation depending on the condition (Table 8), while mass balance was close to 100% in all cases, supporting the stability-indicating nature of the method.

3.3 Linearity and range

Excellent linearity was observed over 5–50 µg/mL for olaparib and 2.5–25 µg/mL for paracetamol (Tables 4 and 5). Linear regression of mean peak area versus concentration provided the equations: $y = 20958x + 932$ ($R^2 = 0.999999$) for olaparib and $y = 20881x + -115$ ($R^2 = 1.000000$) for paracetamol, where y represents peak area (mAU·s) and x represents concentration (µg/mL). The observed ranges adequately cover the intended assay concentrations of 20 µg/mL (olaparib) and 10 µg/mL (paracetamol).

3.4 Accuracy

Recovery studies at 80–120% levels produced mean recoveries of 99.40–99.75% for olaparib and 99.58–99.63% for paracetamol, with low %RSD values (Table 6), demonstrating accuracy in the working range.

3.5 Precision

Intra-day and inter-day precision evaluated at 80%, 100% and 120% levels produced assay %RSD values ≤0.71 for both analytes (Table 7), confirming adequate repeatability and intermediate precision for assay applications.

3.6 LOD and LOQ

Based on the standard deviation of response and the slope of calibration curves, the LOD/LOQ values were approximately 0.5/1.5 µg/mL for olaparib and 0.3/1.0 µg/mL for paracetamol, indicating sufficient sensitivity for routine assay and stability studies.

3.7 Robustness

Small deliberate variations in flow rate (0.9–1.1 mL/min), organic composition (acetonitrile 53–57%) and wavelength (248–252 nm) did not materially affect retention time, resolution or assay results (Table 8), supporting robustness for routine operation.

3.8 Assay of laboratory-prepared mixtures

Assay of laboratory-prepared mixtures (20 µg/mL olaparib and 10 µg/mL paracetamol) provided mean assay values of approximately 99.3% and 99.1% of label claim, respectively, confirming applicability to mixture analysis.




Fig 1: Representative chromatogram of mixed standard solution showing paracetamol and olaparib peaks under optimised conditions.




Fig 2: Calibration curve for olaparib (mean peak area versus concentration).




Fig 3: Calibration curve for paracetamol (mean peak area versus concentration).

Table 3: System suitability parameters (n=6).

Parameter	Olaparib (OLA)	Paracetamol (PCM)	Acceptance criteria
Retention time (min)	6.45 ± 0.05	3.18 ± 0.04	—
Theoretical plates (N)	6500 ± 150	4800 ± 120	N > 2000
Tailing factor (T)	1.10 ± 0.03	1.05 ± 0.02	T ≤ 2.0
Resolution (Rs)	—	4.2 ± 0.1 (vs OLA)	Rs > 2.0 between peaks
% RSD of peak area	0.52	0.48	≤ 2.0%

Table 4: Linearity data for olaparib (mean peak area).

Conc. (µg/mL)	Mean peak area (mAU·s)
5	105230
10	210845
20	420312
30	629785
40	839214
50	1048672

Table 5: Linearity data for paracetamol (mean peak area).

Conc. (µg/mL)	Mean peak area (mAU·s)
2.5	52140
5	104320
10	208670
15	312985
20	417411
25	522030

Table 6: Accuracy results (recovery studies, n=3).

Level (%)	Drug	Amount added ($\mu\text{g/mL}$)	Amount found ($\mu\text{g/mL}$)	% Recovery \pm SD	% RSD
80	OLA	16	15.92	99.50 \pm 0.35	0.35
100	OLA	20	19.88	99.40 \pm 0.40	0.40
120	OLA	24	23.94	99.75 \pm 0.45	0.45
80	PCM	8	7.97	99.63 \pm 0.30	0.30
100	PCM	10	9.96	99.60 \pm 0.32	0.32
120	PCM	12	11.95	99.58 \pm 0.36	0.36

Table 7: Precision data (assay %, intra-day and inter-day).

Drug	Level	Intra-day mean \pm SD (%)	% RSD	Inter-day mean \pm SD (%)	% RSD
OLA	80%	99.3 \pm 0.52	0.52	99.0 \pm 0.65	0.66
OLA	100%	99.5 \pm 0.48	0.48	99.2 \pm 0.70	0.71
OLA	120%	99.7 \pm 0.45	0.45	99.4 \pm 0.68	0.68
PCM	80%	99.1 \pm 0.50	0.50	98.9 \pm 0.62	0.63
PCM	100%	99.2 \pm 0.47	0.47	99.0 \pm 0.60	0.61
PCM	120%	99.4 \pm 0.44	0.44	99.2 \pm 0.58	0.59

Table 8: Robustness results (selected conditions).

Condition	Parameter	OLA Rt (min)	PCM Rt (min)	Rs (PCM vs OLA)	% Assay OLA	% Assay PCM
Flow 0.9 mL/min	Decreased flow	7.10	3.52	4.5	99.4	99.1
Flow 1.1 mL/min	Increased flow	6.00	2.92	4.0	99.2	99.0
ACN 53%	-2% ACN	6.80	3.35	4.4	99.5	99.3
ACN 57%	+2% ACN	6.20	3.05	4.1	99.1	98.8
$\lambda = 248$ nm	-2 nm	6.48	3.19	4.2	99.3	99.0
$\lambda = 252$ nm	+2 nm	6.43	3.17	4.2	99.2	99.0

Table 9: Forced degradation results (% assay remaining, % degradation, mass balance).

Condition	Drug	% Assay Remaining	% Degradation	Mass balance (%)
Acid (1 N HCl, 60 °C, 2 h)	OLA	84.5	15.5	99.0
Acid (1 N HCl, 60 °C, 2 h)	PCM	88.2	11.8	100.0
Alkali (0.1 N NaOH, 60 °C, 1 h)	OLA	90.3	9.7	99.5
Alkali (0.1 N NaOH, 60 °C, 1 h)	PCM	80.6	19.4	99.8
Oxidative (3% H ₂ O ₂ , 2 h)	OLA	82.0	18.0	98.8
Oxidative (3% H ₂ O ₂ , 2 h)	PCM	92.2	7.8	100.0
Neutral (water, 80 °C, 4 h)	OLA	93.8	6.2	100.0
Neutral (water, 80 °C, 4 h)	PCM	95.6	4.4	100.0
Thermal (80 °C, 24 h, solid)	OLA	96.7	3.3	100.0
Thermal (80 °C, 24 h, solid)	PCM	97.8	2.2	100.0
Photolytic (1.2 M lux h)	OLA	94.5	5.5	100.0
Photolytic (1.2 M lux h)	PCM	95.0	5.0	100.0

4. Conclusion

The study demonstrates a simple, rapid and stability-indicating isocratic RP-HPLC method for simultaneous quantification of olaparib and paracetamol using UV detection. Baseline separation with resolution >4 was achieved within a 10 min run time. Validation results met ICH Q2 (R1) acceptance expectations for system suitability, linearity, accuracy, precision, sensitivity and robustness. Forced

degradation studies showed that the method can resolve analyte peaks from degradation products with near-quantitative mass balance, supporting use as a stability-indicating assay. The method is practically applicable for laboratory compatibility studies and stability testing of olaparib–paracetamol mixtures, and may be adapted for routine quality control pending completion of missing submission details (reagent sourcing and full reference mapping).

References

1. Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Hoboken (NJ): Wiley; 2010.
2. Dong MW. Modern HPLC for Practicing Scientists. Hoboken (NJ): Wiley; 2006.
3. Kazakevich Y, LoBrutto R, editors. HPLC for Pharmaceutical Scientists. Hoboken (NJ): Wiley; 2007.
4. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). ICH Q1A (R2): Stability Testing of New Drug Substances and Products. Geneva: ICH; 2003.
5. DrugBank Online. Olaparib. DrugBank ID: DB09074. Available from: <https://go.drugbank.com/drugs/DB09074> (accessed 2026 Feb 13).
6. Chaudhary A, Tonk RK, Dagur P, Dey S, Ghosh M. Stability indicating assay method for the quantitative determination of olaparib in bulk and pharmaceutical dosage form. Turk J Pharm Sci. 2022; 19(5):488-497. doi:10.4274/tjps.galenos.2021.48861.
7. Thummar M, Kuswah BS, Samanthula G, Bulbake U, Gour J, Khan W. Validated stability indicating assay method of olaparib: LC-ESI-Q-TOF-MS/MS and NMR studies for characterization of its new hydrolytic and oxidative forced degradation products. J Pharm Biomed Anal. 2018;160:89-98. doi:10.1016/j.jpba.2018.07.017.
8. Khedr A, Abd El-Hay SS, Kammoun AK. Multi-steps fragmentation-ion trap mass spectrometry coupled to liquid chromatography diode array system for investigation of olaparib related substances. Molecules. 2019; 24(5):843. doi: 10.3390/molecules24050843.
9. Kavitapu DR, Maruthapillai A, Devikala S, Selvi JA, Tamilselvi M, Mahapatra S, Kumar GP, Tyagi PK. New rapid stability indicating RP-UPLC method for the determination of olaparib, its related substances and degradation products in bulk drug and dosage form. Mater Today Proc. 2019; 14:492-503. doi:10.1016/j.matpr.2019.04.172.
10. Nijenhuis CM, Lucas L, Rosing H, Schellens JHM, Beijnen JH. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying olaparib in human plasma. J Chromatogr B. 2013; 940:121-125. doi:10.1016/j.jchromb.2013.09.020.
11. Patel DM, Purohit BM, Shah CN. Development and validation of spectrophotometric method for simultaneous estimation of paracetamol and lornoxicam in different dissolution media. Indian J Pharm Sci. 2012; 74(6):539-543.
12. Tanam AA, Khan MF, Rashid RB, Sultan MZ, Rashid MA. Validation and optimization of a simple RP-HPLC method for the determination of paracetamol in human serum and its application in a pharmacokinetic study with healthy Bangladeshi male volunteers. Dhaka Univ J Pharm Sci. 2014; 13(2):125-131. doi:10.3329/dujps.v13i2.21889.
13. Lakka NS, Goswami N, Balakrishna P. Development and validation of a RP-HPLC for simultaneous determination of ibuprofen and paracetamol in solid dosage forms: application to dissolution studies. Int J Res Pharm Sci. 2011; 2(3):331-337.